LONG MINI-FUTURE - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 01:50:40 2024-05-31 pm EDT | ||
| 8.51 EUR | +13.62% |
|
| Current month | +140.40% | ||
| 1 month | +140.40% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 8.51 | +13.62% |
| 24-05-30 | 7.49 | -4.22% |
| 24-05-29 | 7.82 | -3.93% |
| 24-05-28 | 8.14 | -13.50% |
| 24-05-27 | 9.41 | +4.21% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 01:50 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM656J |
| ISIN | DE000VM656J0 |
| Date issued | 2023-12-15 |
| Strike | 360.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.88 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.41 € |
|---|---|
| Lowest since issue | 3.19 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Certificates
- Certificat
